

FDA-APPROVED OVARIAN CANCER TREATMENTS

Generic	Brand	Strength	Form	Usual Dose
ALKYLATING AGENT				
carboplatin	—	10mg/mL	soln for IV infusion	<i>Advanced ovarian cancer (previously untreated):</i> 300mg/m ² on Day 1 every 4wks for 6 cycles. <i>Recurrent ovarian cancer:</i> 360mg/m ² on Day 1 every 4wks
cisplatin	—	1mg/mL	soln for IV infusion after dilution	75–100mg/m ² IV per cycle once every 3–4wks on Day 1
		50mg/vial	pwd for IV infusion after reconstitution and dilution	
cyclophosphamide	—	25mg, 50mg	tabs	1–5mg/kg/day
		500mg, 1g, 2g	pwd for inj after reconstitution	40–50mg/kg in divided doses over 2–5 days or 10–15mg/kg every 7–10 days or 3–5mg/kg twice weekly
melphalan	—	2mg	scored tabs	0.2mg/kg/day for 5 days; repeat every 4–5wks
thiotepa	—	15mg	pwd for IV, intravesical, or intracavitary administration after reconstitution	0.3–0.4mg/kg IV once every 1–4wks
ANTIBIOTICS (CYTOTOXIC)				
doxorubicin	—	10mg, 20mg, 50mg	pwd for IV inj after reconstitution	<i>Monotherapy:</i> 60–75mg/m ² every 21 days. <i>Combination therapy:</i> 40–60mg/m ² every 21 to 28 days
		2mg/mL	soln for IV inj	
doxorubicin (liposomal)	Doxil	2mg/mL	dispersion for IV infusion after dilution	50mg/m ² once every 4wks; continue for ≥4 cycles as tolerated. Initial rate: 1mg/min; may increase rate to complete infusion over 1hr if no infusion reactions occur.
ANTIMETABOLITE				
gemcitabine	—	200mg, 1g, 2g	pwd for IV infusion after reconstitution	1000mg/m ² on Days 1 and 8 of each 21-day cycle; give with carboplatin AUC 4 administered on Day 1 after gemcitabine
	Infigem	1200mg/120mL, 1300mg/130mL, 1400mg/140mL, 1500mg/150mL, 1600mg/160mL, 1700mg/170mL, 1800mg/180mL, 1900mg/190mL, 2000mg/200mL, 2200mg/220mL	soln for IV infusion	
ANTIMICROTUBULE AGENTS				
paclitaxel	—	6mg/mL	soln for IV infusion after dilution	<i>Previously untreated ovarian cancer:</i> 175mg/m ² IV over 3hrs + cisplatin; or 135mg/m ² IV over 24hrs + cisplatin; repeat every 3wks. <i>Previously treated ovarian cancer:</i> 135mg/m ² or 175mg/m ² over 3hrs every 3wks
POLY (ADP-RIBOSE) POLYMERASE INHIBITOR				
niraparib	Zejula	100mg	caps	<i>First-line maintenance of advanced ovarian cancer:</i> start within 12wks after most recent platinum-containing regimen; (patients <77kg or with platelets <150000/μL): 200mg once daily; (patients ≥77kg and platelets ≥150000/μL): 300mg once daily. <i>Maintenance of recurrent ovarian cancer:</i> start within 8wks after most recent platinum-containing regimen; 300mg once daily. <i>Maintenance of advanced ovarian cancer after ≥3 prior chemotherapies:</i> 300mg once daily. <i>All:</i> continue until disease progression or unacceptable toxicity.
olaparib	Lynparza	100mg, 150mg	tabs	300mg twice daily. <i>First-line maintenance of BRCA-mutated or HRD-positive advanced ovarian:</i> continue until disease progression, unacceptable toxicity, or completion of 2yrs of treatment. Discontinue if complete response at 2yrs; may treat beyond 2yrs in those with evidence of disease if provider can derive further benefit from continuous treatment. <i>Maintenance of recurrent ovarian or gemline BRCA-mutated advanced ovarian:</i> continue until disease progression or unacceptable toxicity. <i>In combination with bevacizumab:</i> give bevacizumab (15mg/kg every 3wks) for total of 15mos (see full labeling).
rucaparib	Rubraca	200mg, 250mg, 300mg	tabs	600mg twice daily until disease progression or unacceptable toxicity
TOPOISOMERASE INHIBITOR				
topotecan	Hycamtin	4mg	pwd for IV infusion after reconstitution and dilution	1.5mg/m ² daily for 5 consecutive days starting on Day 1 of a 21-day cycle
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR				
bevacizumab	Avastin	100mg, 400mg	soln for IV infusion after dilution	<i>Recurrent ovarian cancer (platinum-resistant):</i> 10mg/kg every 2wks with either paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or, 15mg/kg every 3wks with topotecan (every 3wks); <i>(platinum-sensitive):</i> 15mg/kg every 3wks with carboplatin/paclitaxel for 6 cycles and up to 8 cycles or carboplatin/gemcitabine for 6 cycles and up to 10 cycles; followed by bevacizumab 15mg/kg every 3wks as a single agent until disease progression. <i>Stage III/IV ovarian cancer:</i> 15mg/kg every 3wks with carboplatin/paclitaxel for up to 6 cycles; followed by bevacizumab 15mg/kg every 3wks as a single agent, for a total of up to 22 cycles or until disease progression, whichever occurs first.
bevacizumab-awwb	Mvasi	100mg, 400mg	soln for IV infusion after dilution	
bevacizumab-bvzr	Zirabev	100mg, 400mg	soln for IV infusion after dilution	

NOTES

Not an inclusive list of medications and/or doses. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 2/2022)